Compared with earlier more restricted sequencing technologies, identification of rare disease variants using whole-genome sequence has the possibility of finding all causative variants, but issues of data quality and an overwhelming level of background variants complicate the analysis.
INTRODUCTION
With recent advances in sequencing technology and decreasing cost (Hayden, 2014) , the use of next-generation sequencing technology is becoming wide spread in clinical practice, especially for rare and undiagnosed genetic diseases. Until recently, most applications have utilized sequence of panels of exome sequence for relevant genes or whole-exome sequencing. Whole-genome sequencing (WGS) is now increasingly being used. The advantages and disadvantages of this level of sequencing are not yet clear. On the one hand, it has the potential to improve patient diagnosis and care because of a much more comprehensive coverage of possible causal variants. On the other hand, the difficulty of accurate clinical interpretation of causal variants, especially novel ones, increases with increasing amounts of sequence coverage. Even for limited panel sequencing, issues of which variants to report as clinically relevant are serious. Also, diagnostic success rates are not high. The current diagnostic rate for rare diseases, including WGS as well as whole-exome sequencing is 25%-40% (Baynam et al., 2016; Sawyer et al. 2016; Stavropoulos et al., 2016; Wright et al., 2015) . Thus, a key question is: how can we maximize the diagnostic efficacy of genomic data? Answering this question relies on contributions from the computational biology community.
Identification of causative variants for rare pediatric diseases from next-generation sequencing data presents three types of challenges:
First, identification of a correct disease definition from wide variety of symptoms involving different parts of the body. In this regard, Phenomizer (Kohler et al., 2009 ) utilizes semantic similarity metrics between query phenotypes and the Human Phenotype Ontology (HPO) (Köhler et al., 2014) to identify candidate diseases consistent with a set of clinical symptoms. For this Critical Assessment of Genome Interpretation (CAGI) challenge, disease definitions were available in the supplementary material of Stavropoulos et al. (2016) . The second challenge is identification of relevant gene(s) for the disease. There are several computational methods that address this problem. Phenolyzer (Yang, Robinson, & Wang, 2015) integrates various gene-disease databases as well as gene-gene relationship database information to obtain a score to rank candidate disease genes. Exomiser Smedley et al., 2015) uses a series of algorithms to prioritize disease genes utilizing protein interaction networks, clinical relevance, and cross-species phenotype comparisons. Phen-Gen (Javed, Agrawal, & Ng, 2014 ) integrates patient's phenotypic symptoms (through Phenomizer) as well as genotypic data (utilizing a gene-gene interaction network) in a Bayesian framework to prioritize candidate disease genes. As described later, we made use of the phenotype information provided with the challenge together with some inter-species data to identify relevant genes. The third challenge is identification of causative variants in a relevant gene. Most of the methods utilize non-disease-specific variant prioritization tools for this purpose. Phenolyzer uses wANNOVAR (Chang & Wang, 2012) , whereas Exomiser uses Jannovar (Jäger et al., 2014) together with a frequency filter and predicted pathogenicity values of different missense pathogenicity prediction methods. In Phen-Gen, coding variant prioritization is done using the predicted damaging effect of coding mutations, including non-synonymous, nonsense, splice sites, and indels. For non-coding variants, the method uses a combination of five annotations for predicted damaging effect, including transcription factor binding site and DNase hypersensitive site information. Recently, Smedley et al. (2016) developed Genomiser to prioritize non-coding variants from WGS data, using a Random Forest classifier at each position in the genome.
This classifier has 26 numeric features, including various conservation scores together with ENCODE methylation and acetylation information. A manually curated set of 453 unique, non-coding Mendelian disease-associated mutations are used as the positive training set and non-coding differences between human and inferred ancestral primate genome sequence provide the negative training set. In this CAGI challenge, our approach to causative variant identification also utilizes non-disease-specific variant prioritization tools, applied to both coding and non-coding variants.
All the methods for assigning pathogenicity have been benchmarked against rare disease information sources such as HGMD (Stenson et al., 2014) , but none has been evaluated in blind testing, since limited opportunities are available to do so. The CAGI is an organization that conducts blind testing of these and other computational methods related to genome interpretation. In CAGI4, there was a challenge which probed the computational community's ability to make use of WGS data for clinical diagnosis (https://genomeinterpretation .org/content/4-SickKids_clinical_genomes).
The challenge data were provided by the SickKids genome clinic (http://www.sickkids.ca/) in Toronto. The clinic is a multidisciplinary test bed that supports a wide range of research into the clinical uses of WGS, from development of new bioinformatics pipelines and counseling models to health economics and bioethics studies. For this challenge, they provided clinical phenotypic information and wholegenome sequence data for 25 patients who had been referred for pediatric genetic services (Stavropoulos et al., 2016) . These 25 are part of the first set of 100 cases examined with WGS data, and are all cases where the SickKids pipeline did not find any diagnostic variant. The CAGI challenge was to identify diagnostic variants (those matching the clinical phenotypic description) and predictive secondary variants (not related to the reported clinical phenotype, if present) in the 25 cases. Since these were all cases where no diagnostic variants had been found, the SickKids Genome Clinic undertook to validate some of the more promising predictions by Sanger sequencing (to ensure the proposed variants were not sequencing errors) and reverse phenotyping (consulting with the referring physicians as to whether implicated genes are consistent with observed phenotypes).
Here, we report results for the SickKids challenge. We adopted a comprehensive exploratory approach, including both coding and non-coding regions, for prioritizing candidate disease genes and variants for these 25 cases. A tiered classification scheme was used to find candidate causative variants, based on the strength of the evidence for disease relevance. Candidate variants sets were filtered on the basis of population minor allele frequency (MAF) and conformity to the required inheritance model. Remaining variants were ranked on the degree to which each could account for the patient phenotypes.
The results allowed us to analyze the performance of a number of aspects of the methods.
MATERIALS AND METHODS

SickKids challenge phenotypes and compilation of the candidate gene list
Patient identities were derived from supplementary Table 4 of Stavropoulos et al. (2016) , which provided a key linking each challenge ID to the corresponding patient ID. The clinical phenotype descriptions for each of the 25 patients provided with the challenge were in the form of PhenoTips annotations (Girdea et al., 2013) , using HPO terms.
For each patient, a list of candidate genes that might harbor causative variants was compiled from information in the HPO database (Build #102) (Köhler et al., 2014) and the dbNSFP database (version 3.1a) (Liu, Wu, Li, & Boerwinkle, 2016) . The latter includes genes related to phenotypes observed in humans as well as in a mouse database (Eppig et al., 2015; Georgi, Voight, & Bućan, 2013) . The secondary gene list consisted of 56 genes that may contain actionable variants unrelated to reported symptoms, provided in the ACMG guidelines (Table 1 in Green et al., 2013) .
Annotation of VCF files and quality control filters
Sequence data for the patients was available through the CAGI challenge site, and consisted of VCF files containing SNVs (single nucleotide variants), Indels (Insertion/deletions), CNVs, SVs (Structural Variants), and MEI (Mobile Element Insertions) output from the Complete Genomics assembly pipeline 2.5. We annotated variants in these files using Varant (https://doi.org/10.5060/D2F47M2C). Annotations include region of occurrence (intron, exon, splice site or intergenic), observed MAFs from 1000 Genomes data (Auton et al., 2015) and the ExAC database (Lek et al., 2016) (whichever is larger), mutation type, predicted pathogenicity of missense variants, and associated phenotypes reported in OMIM (Hamosh, Scott, Amberger, Bocchini, & McKusick, 2005) and ClinVar (Landrum et al., 2016) . The RefGene (Pruitt et al., 2014) For data meeting these criteria, the median read depth is around 40× and the median allelic depth ratio of "alt" and "ref" alleles is around 1.1 for rare (<1% frequency) missense mutations. We also checked whether or not the SNVs and indels are in low complexity regions (LCRs), following (Li, 2014) , as annotated in Varant (https://doi. org/10.5060/D2F47M2C).
Ethnicity calculation
An in-house procedure was used to estimate whether each individual's genomic data belongs to an African (AFR) population or not.
Population-specific allele frequency (AF) from the 1000 Genomes Phase 3 data release on May 2013 (Auton et al., 2015) 
Candidate causative variants
Variant selection was made in two steps. In the first step, candidate causative variants were extracted from the genes selected for each patient. Each variant with less than 5% population frequency was assigned to one of seven categories, based on likelihood of pathogenicity and variant type. Variants were required to conform to the expected inheritance pattern. The selection scheme is shown in Figure 1 . In the second step, final prioritized causative variants were selected from the candidates based on careful examination of phenotypic features.
All accepted high quality variants with population frequency <5% in either 1000 Genomes data (Auton et al., 2015) or in the ExAC database (Lek et al., 2016) (whichever is higher) were categorized using a tiered The missense threshold is based on calibration against HGMD, where 70% of mutations with two out of three reporting methods predicting deleterious were found to be pathogenic (Supp. Fig. S1 ).
Category 3 (C3): Missense mutations with at least one method reporting deleterious, but less than two out of three of methods doing so. Category 7 (C7): All CNV, SV, and MEI variants not included in a lower category.
Most candidate causative variants are in the first three categories (primarily coding), together with some non-coding variants in category 6. These variants were further subdivided according to frequency.
Frequency bin 1: Novel mutations (not seen in 1000 Genomes and ExAC).
Frequency bin 2: Variants with population frequency >0 and <=0.5%
Frequency bin 3: Variants with population frequency >0.5% and
<=1.0%.
Frequency bin 4: Variants with population frequency >1.0% and
<5.0%.
The set of variants found in each gene was evaluated for consistency with that gene's OMIM inheritance pattern (autosomal dominant, autosomal recessive, compound heterozygous, pseudo autosomal recessive, or X-linked recessive). Since phase information was generally not available, when two variants were selected to fulfill the inheritance pattern, it was assumed they are on different copies of the gene. About 7% of the selected genotypes had phase information and for these we checked for consistency with a compound heterozygous model, where appropriate.
Prioritized causative variants
Final prioritized causative variants were selected from the candidate list on the basis of a more careful, by hand, match of patient and gene Speculative Match: When the OMIM disease description for the gene partially overlaps with the patient's phenotype, but the variant is unlikely to be causative, for example a SV in an intergenic region near an appropriate gene or completely within an intron of an appropriate gene, such that there is no obvious mechanism of action. These matches are usually from Category C7.
Searching for predictive secondary variants
The protocol described above (considering only the first three categories) was also used to identify incidental findings, putative secondary variants (following ACMG recommendations) in the 56 ACMG "secondary" genes, using inheritance models from Table 1 in the 2013 ACMG guidelines (Green et al., 2013) .
RESULTS
Demographics, symptoms, and relevant genes
The 25 patients ranged in age from 1 to 18 years, with an average of 5.8. There are 13 males and 12 females. Figure 2 shows the Table S1 ). Some of these specific clinical phenotypes are relatively common among patients, for example, decreased body weight, global developmental delay, short stature, and microcephaly. Supp. Figure S2 shows the distribution of the number of candidate genes corresponding to the specific clinical phenotypes of each patient (as collected from the HPO and dbNSFP databases, details in Materials and Methods). There are a total of 3,306 genes related to a total of 243 specific clinical phenotypes for the 25 patients. The number of genes ranges from 161 to 1,884 per patient, with an average of about 989 genes. The number of specific clinical phenotypes per patient ranges from 5 to 24, with an average of about 13. There is a wide variation in the number of candidate genes per phenotype, from 1,242 genes for "morphological abnormality of the central nervous system," 679 genes for "seizures," and 464 genes for microcephaly to only one gene for "pulmonary artery hypoplasia"
and one gene for 'paroxysmal lethargy' (Supp . Table S2 ). This variation largely reflects the range of generality versus specificity of the phenotypic description. Specific clinical phenotypes with a large number of genes (such as global developmental delay or short stature) are usually not very useful for finding causative variants because of low specificity. Figure 3 shows the distribution of reported common, rare, and novel variants (including SNVs and indels) across the whole genome in the 25 patients. In general, there are a large number of novel (not found in1000 Genomes Phase3 or ExAC database) variants in these samples (on average 290,000 per sample). There are four patients with significantly more reported (P value < 0.0001, chi-square test) F I G U R E 3 Distribution of novel, rare, and common variants in the 25 patients. The four individuals with higher counts were found to be of African ethnicity novel, rare, and common variants than are found in the rest of the patients. Ethnicity analysis (see Materials and Methods) supports an AFR origin of these samples. We did not differentiate between non-AFR groups in rest of the CAGI samples. A possible explanation for the discrepancy in rare variants between the CAGI samples and 1000genome data is a higher error rate in the CAGI samples. LCRs are expected to have more sequencing errors (Li, 2014) , and indeed there is a roughly twofold excess in the CAGI AFR samples and roughly fivefold excess in CAGI non-AFR samples (Table 1) , but as only a small fraction of the data (3%-5%; Table 1 ) lie in these regions, that cannot account for the overall difference.
Distribution of rare and novel genetic variations
There is also a significant (P < 0.0001, chi-square test) excess of rare variants in the CAGI samples compared with 1000 Genome ones in non-LCRs (Table 1) . In exonic regions, there is a statistically significant excess in rare non-synonymous variants (P < 0.0001, chi-square test, for both AFR and non-AFR groups), rare synonymous variants (P < 0.0001, chi-square test, for non-AFR group only), frameshift indels (P < 0.0001, chi-square test, for both AFR and non-AFR groups) and to some extent in splice site variants (P = 0.015 for AFR, 0.0013 for non-AFR) (Table 1) .
Altogether, there are a total of 257,234 novel (not previously seen in the more than 60,000 exomes in ExAC or in the 1000 Genomes) SNVs across the whole genome that occur in two or more of the 25 patients.
In just exonic regions, there are 2,122 such overlapping novel SNVs in 790 genes (Supp. Fig. S3 ) with an average of 1800 novel SNVs per individual. Application of more stringent SNV GQ filters (>20 for homozygous and >40 for heterozygous calls) reduces the average number of overlapping novel exonic SNVs per individual from 1,800 to 1,600, still a large number. 60% of the novel exonic SNVs for each individual (on average 1,100) are found in two or more patients. 
Prioritized causative variants
The initial search for final prioritized causative variants was over candidate causative variants in the C1, C2, and C3 categories.
Post-challenge, the analysis was extended to prioritize variants from the C6 (non-coding) category. As described in Materials and Methods, for each gene implicated by one or more candidate variants, we by uni-parental disomy at chromosome 14 (UPD14) (both chromosome 14 copies inherited from the father). This case would require further experimental analysis to confirm. As noted earlier, all prioritized variants considered are at least GQ "PASS" quality. Under the more stringent Complete Genomics guidelines there is only one borderline homozygous variant (GQ = 20) and one borderline heterozygous (GQ = 40). All other variants are above these thresholds. Figure 7 shows the distribution of underlying molecular mechanisms for the prioritized variants in the C1, C2, C3, and C6 categories in F I G U R E 7 Distribution of prioritized variants with defined molecular mechanism of action in different frequency bins (novel, >0 and <0.5%, >0.5% and <1%, >1% and <5%) for the C1 (annotated as pathogenic), C2 (predicted high impact), C3 (lower impact), and C6 (non-coding) categories. The majority of the prioritized variants are missense 
Molecular mechanisms underlying prioritized causative variants
Exonic variants dominate final prioritization
The composition of the variants changed markedly as these moved through the pipeline (Fig. 8) . Variants from the selected genes for each patient were included in this analysis, including contributions from a total of 3,306 genes. The initial set of GQ filtered, low frequency (<5%) SNVs and indels is composed of 96% intronic (194,958 variants) together with 2% (4,618) UTR variants, and only 0.7% missense (1,412) (Fig. 8A, outer circle) . The middle circle shows the composition of the candidate causative variants. Here, the missense variants fraction jumps to 65% (835 variants) (Fig. 8A, middle circle) . There are smaller number of intronic (28%, 353 variants) and UTR (2%, 28 variants), providing possible regulatory variants (Fig. 8B ). The inner circle shows the composition of the prioritized causative variants. For 23 out of the 25 patients, there is at least one prioritized causative variant in an exon (a total of 46, 88%) ( Fig. 8B ) and 67% of these variants are missense (31 variants). There are also prioritized four variants from intronic regions and two from UTRs.
Role of protein structure destabilization
In rare, monogenic disease, missense mutations often affect protein function through destabilization of protein three-dimensional structure (Yue & Moult, 2006; Yue, Li, & Moult, 2005) . Out of the 31 prioritized missense mutations, seven have adequate structural coverage (the wild-type residue is present in an experimental structure or in a model based on 40% or higher sequence identity to the protein domain of interest) for analysis of this factor. Of these, two are predicted (Yue et al., 2005) to significantly destabilize the corresponding protein structure, suggesting a detailed mechanism of action at the molecular level. Both of these are relatively high frequency variants (1%-5% F I G U R E 9 A: Location of the seven mutations in the voltage gated potassium ion channel, KCNB1, homo-tetramer, colored by chain (six de novo mutations in previous studies and one prioritized validated diagnostic variant in this study). Mutations (red sticks) are shown in one of the chains (modeled from PDB ID: 2R9R; S1, S4, S5, and S6 helices are labeled). B: Expanded view of part of the S1 helix containing the newly discovered diagnostic variant Leu 208 (magenta)-to-Pro (yellow). The mutation lies in the S1 helix such that it may destabilize the domain, and is in a region likely involved in ligand binding
Diagnostic usefulness of the predictions
The SickKids data providers decided to follow-up on some of the variants prioritized by at least two of the four CAGI teams taking part in the challenge. Validation information has so far been returned for four of these, including three we prioritized. Of these three, two did not pass validation, one because it was not confirmed by Sanger sequencing, the other because the referring physician did not consider it an adequate fit to the patient's phenotype. However, the third variant we prioritized (and which was also found by another CAGI team), was accepted by the referring physician as providing an explanation for the patient's phenotype of intractable epilepsy. Thus, our analysis has provided a diagnosis for a previously intractable case. We missed the in the S4, S5, and S6 helices (Fig. 9A ). All are predicted deleterious by SNP3D profile (Yue & Moult, 2006) . Five of the six mutations are predicted to destabilize the structure by SNPs3D structure (Yue et al., 2005) , demonstrating that destabilization is a common mechanism for this disease. The sixth, V378A, points directly into the pore.
The new mutation, p.L208P, is at the end of the S1 helix -beginning of S1-S2 linker, on the boundary of the membrane and extracellular region (Fig. 9A) , and is also predicted deleterious by SNPs3D profile.
SNPs3D structure analysis finds p.L208P does not substantially affect thermodynamic stability, although this result may partly reflect the low accuracy of the template structure in this region (crystallographic B factors are approximately 55). Inspection of the structural context shows the residue is on the protein surface, but that there are some clashes of the proline side chain with the surrounding backbone, as expected for the introduction of a proline residue into a helix (Fig. 9B) .
This is the first disease mutation found in the S1 helix, the role of which in channel control is not yet clear. A recent study in a related potassium channel has implicated the S1-S2 linker in binding of a regulatory ligand, defensin (Feng et al., 2015) .
Predictive secondary variants
Following the same procedure (using only the first three categories, details in Materials and Methods) used for identification of causative variants responsible for reported disease phenotypes, we selected a total of 22 prioritized actionable secondary variants in the 56 ACMG approved genes for these 25 patients (Supp . Table S4 and Supp. Fig. S5 ).
As with the candidate causative variants, most of the variants (68%) are novel and most of the variants (64%) are in Category C2, four of the five prioritized Category C1 secondary variants are missense, and the fifth, in BRCA1, is a frameshift insertion. There are three novel frameshift inserts in Category C2, and all other C2 and C3 category variants are high impact missense (at least two out of three or three out of four methods predicting deleterious for the C2 category and less than 2/3 of methods predicting deleterious for the C3 category).
According to ACMG guidelines (Richards et al., 2015) , the three novel variants in Category C1 and the three frameshift insertions in Category C2 may be reported as pathogenic. The remaining 16 missense variants are officially "supporting pathogenic" or "VUS." The SickKids data providers also followed-up on some submitted novel secondary variants. Of those that we submitted, the three novel frameshift insertions from C2 category, including one BRCA1 frameshift insert, were discarded because of low read depth. Another BRCA1 frameshift insert from the C1 category also did not validate by Sanger Sequencing.
A C1 category novel predicted deleterious missense variant from FBN1 (which is classified likely pathogenic by ClinVar and DM (disease mutation) by HGMD) was not considered as pathogenic by the data providers.
DISCUSSION
New results for WGS data together with systematic clinical phenotypic descriptions show promise for improved diagnostic performance in cases of rare and undiagnosed pediatric diseases (Gilissen et al., 2014; Stavropoulos et al., 2016; Willig et al., 2015) . In support of this view, the SickKids WGS study of 100 rare pediatric cases was more successful than other technology platforms (including chromosome microarray analysis [CMA] alone and together with targeted gene sequencing) in identifying diagnostic variants for 34 patients (8% by CMA alone and 13% by CMA together with targeted gene sequencing) (Stavropoulos et al., 2016) . The CAGI4 SickKids clinical genome challenge provided a means of evaluating our current ability to find causative variants in a set of especially difficult rare pediatric cases: 25 cases where the SickKids analysis pipeline did not find any diagnostic variant (Stavropoulos et al., 2016) . These cases indeed proved difficult for us and other CAGI participants, but for two patients, diagnostic variants were found, one by us and another group, and another by two other groups. We took part in the challenge to test our methods, and the potentially useful medical outcome was an unexpected and pleasing bonus.
Pipeline features
For this CAGI4 challenge, we developed an analysis pipeline that first objectively classified all variants found in a set of candidate genes into consists of exonic variants most likely to cause substantial loss of function. The majority (59%) of these are missense. Reliable interpretation of this type of variant is an unsolved problem. As a consequence, current ACMG guidelines (Richards et al., 2015) consider computational impact prediction for missense mutations only as supporting evidence of pathogenicity, even when multiple methods agree.
One advantage of using whole genome data over whole exome or gene panel data is the inclusion of non-coding variants, which may have a role in some rare diseases (Postma et al. 2015; Smedley et al., 2016) .
In our pipeline, we considered non-coding variants in UTRs and introns, using a stringent CADD score criterion (Kircher et al., 2014) to estimate possible pathogenicity. On that basis, six such non-coding variants were prioritized ( Fig. 8 and Supp. Table S3 ). We also considered the other types of variant in the SickKids data, including MEI, CNV, and SVs, and prioritized a small number of SVs, but no MEI or CNV.
Phenotypic information for the patients was provided in the form of HPO terms (Köhler et al., 2014) , and these were used to identify candidate genes. Generally, pathogenic variants in a particular gene are associated with range of symptoms, and matching these with the patient HPO terms is not easily automatable. We made subjective matches, based on the degree of overlap of detailed phenotype features and the OMIM disease description for the selected gene, assigning "probable," "possible," or "speculative," confidence of cause for each variant on that basis.
Data quality considerations
There are a large number of novel exonic SNVs (an average of 1,600
per individual), not previously observed in the ∼60,000 exomes in the ExAC database, whereas a maximum of 300 such novel exonic variants are found in the 1000 Genomes Phase3 individuals relative to ExAC database (Lek et al., 2016) . There is also a high level of recurrence of these not previously observed variants (SNVs and indels) in more than one patient-for the 25 patients, there are a total of 257,234 novel SNVs that occur in more than one individual. At the individual level, on average 60% of novel exonic SNVs are shared by others, even in this small sample set.
These observations suggest either a significant level of false variant calls in the Sick Kids data and/or a significant level of missed variants in the 1000 Genomes and ExAC data. These data sets were obtained with different sequencing technologies and variant calling procedures (an Illumina platform and GATK analysis pipeline for 1000 Genomes and Complete Genomics sequencing technology and assembly pipeline for the Sick Kids data). Several studies have compared results for these technologies and found significant discrepancies (Goldfeder et al., 2016; Lam et al., 2011; Wall et al., 2014) . In particular, Wall et al. (2014) estimated error rates based on discrepancies in variant calls in blood and saliva DNA samples among four individuals using the two tech- It should be emphasized that these data difficulties are partly an artifact of the CAGI challenge. In the Sick Kids clinic, Sanger sequencing is routinely used to check any suggested prioritized causative variant. It is likely that low depth next-generation sequencing followed by validation using Sanger sequencing is the most economical approach at present.
Reporting of predictive secondary variants to the patients is a highly debated subject (Shahmirzadi et al., 2014) , because of potential false positives (Kohane et al. 2006a,b; Biesecker, 2013; Hegde et al., 2015) .
Indeed, we found 22 candidate variants in the ACMG approved 56 gene set, and is likely nearly all of these are sequence errors.
Extent and nature of prioritized pathogenic variants
The analysis pipeline we developed led to the reporting of one or more prioritized causative variants in the coding region for 22 of the 25 cases. In one of the other three patients, the expected cause of the coat hanger ribs phenotype is uni-parental disomy at chromosome 14 and parental sequence data is required for a definitive diagnosis. In the remaining two patients we prioritized SVs in the intergenic regions, close to relevant genes, but could not identify any potential pathogenic mechanism for these. Overall, the majority (59%) of reported variants are missense, followed by frameshift indels (22%). Variants from noncoding regions sometimes support the symptoms not covered by the prioritized exonic variant. An example is the validated diagnostic prediction based on a missense mutation in KCNB1, accounting for the intractable epilepsy symptoms in the patient, but not for another symptom, macrocephaly. We found an indel in the intronic region of the gene DNMT3A (OMIM disease Tatton-Brown-Rahman syndrome or overgrowth syndrome) which supports that phenotype. Although SVs including CNVs are relatively common (8% diagnostic rate for CNVs in SickKids study (Stavropoulos et al., 2016) ) in children with mental retardation or other congenital anomalies (Cooper et al., 2011; Vultovan Silfhout et al., 2013; Wang et al., 2016) , we did not find any novel non-overlapping pathogenic CNVs or MEIs in this small sample set.
Since these are all cases where no diagnostic variants were found in the initial Sick Kids analysis, the high fraction of cases with apparently viable causative variants is surprising. Two factors partly explain the result. First, as discussed earlier, the false call rate in the VCF files appears to be high, and quite a few (four out of six prioritized variants) of our proposed variants have been ruled out by Sanger sequencing at Sick Kids. Second, we used a moderately permissive filter for missense variants, requiring that at least two out of three methods report deleterious. This threshold is expected to have an up to 30% false positive rate (Supp. Fig. S1 ). Still, using a stricter criterion of four out of four or three out of three methods reporting deleterious only reduces the number of candidate causative variants by about 50%.
There are generally a large number of reported HPO phenotypes for these patients (total 243, with an average of 13 HPO terms per patient), such that in many cases there is no known single gene in which a variant could produce all the symptoms. For about two-thirds (16 out of the 25 patients) of the cases we found prioritized causative variants in two or more candidate genes that together could produce the reported phenotypes, implying that there are multiple independent causes contributing to the phenotypic profile. However, the large number of suspected false variant calls makes it difficult to be sure in any particular case without further follow-up by Sanger sequencing. Similarly, we found a large number of prioritized pathogenic secondary variants in 13 genes out of 56 ACMG "secondary" genes, recommended by the ACMG guidelines (Green et al., 2013) as appropriate for searching additional risk factors. Of these, two novel frameshift inserts in BRCA1 have been checked at Sick Kids by Sanger sequencing and neither validated.
The diagnostic success
As noted earlier, of the variants we prioritized as causative of the reported phenotypes for these 25 cases, five have so far been checked by Sanger sequencing. Although two did not validate, of the remaining three, one is considered by the referring physician as providing a convincing explanation for the observed phenotype. Given the difficulty of these cases, this is a satisfying result.
CONCLUSIONS
Why are these 25 cases difficult to diagnose? These are a subset of the first 100 cases passed through the Sick Kids whole-genome pipeline, and diagnostic variants were found in 34 cases (Stavropoulos et al., 2016) . The Sick Kids authors consider this success is partly due to the inclusion of other variant types (SVs) besides single base differences, with eight cases diagnosed in that way. There are multiple possible reasons why these 25 cases are recalcitrant. First, causative variants may lie in intergenic regions of the genome, not included in our or the Sick Kids analysis. Second, the causes may lie in genes not so far associated with the relevant phenotypes. Novel candidate gene discovery based on cross-species information might provide clue in these cases, although those findings will be clinically non-reportable. Third, the suspected high rate of false variant calls implies a significant rate of missed variants. If so, that is a price paid for adopting a strategy of moderate quality coverage on full sequence followed by Sanger validation. In support of a role for this factor, one study (Goldfeder et al., 2016) has found that 23% of pathogenic and likely pathogenic ClinVar variants are not in high confidence regions (where SNV and indel genotypes are concordant from five different sequencing technologies). Fourth, epigenetic causes of rare disease (Bjornsson, 2015) are a further factor of currently unknown significance. Fifth, the qualitative impressions of a referring physician about a patient's phenotypes may not be precisely captured by phenoTips.
The original goal of this challenge was to objectively test the efficacy of pipelines such as the one used here by seeing how many patient phenotypes and genotypes could be successfully matched. A data leak prevented that assessment. Nevertheless, as the analysis in this article shows, it has been possible to use the new pipeline to explore and clarify many aspects of the challenge data and the prioritized causative variants, and there was one diagnostic success on these difficult cases.
We look forward to other CAGI challenges of this type, permitting a full objective evaluation of the methods.
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